Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity.
Affiliation
Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA.Issue Date
2004-03-23
Metadata
Show full item recordAbstract
The notorious resistance of melanoma cells to drug treatment can be overcome by expression of a 50-aa peptide derived from activating transcription factor 2 (ATF2(50-100)). Here we demonstrate that ATF2(50-100) induced apoptosis by sequestering ATF2 to the cytoplasm, thereby inhibiting its transcriptional activities. Furthermore, ATF2(50-100) binds to c-Jun N-terminal kinase (JNK) and increases its activity. Mutation within ATF2(50-100) that impairs association with JNK and the inhibition of JNK or c-Jun expression by RNA interference (RNAi) reduces the degree of ATF2(50-100)-induced apoptosis. In contrast, TAM67, a dominant negative of the Jun family of transcription factors, or JunD RNAi attenuates sensitization of melanoma cells expressing ATF2(50-100) to apoptosis after treatment with anisomycin, which is used as a model drug. Mutations within the JNK binding region of ATF2(50-100) or expression of TAM67 or JunD RNAi attenuates inhibition of melanoma's tumorigenicity by ATF2(50-100). We conclude that inhibition of ATF2 in concert with increased JNK/Jun and JunD activities is central for the sensitization of melanoma cells to apoptosis and inhibition of their tumorigenicity.Citation
Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. 2004, 101 (12):4222-7 Proc. Natl. Acad. Sci. U.S.A.Journal
Proceedings of the National Academy of Sciences of the United States of AmericaDOI
10.1073/pnas.0400195101PubMed ID
15010535Type
ArticleLanguage
enISSN
0027-8424ae974a485f413a2113503eed53cd6c53
10.1073/pnas.0400195101
Scopus Count
Collections
Related articles
- An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis.
- Authors: Bhoumik A, Huang TG, Ivanov V, Gangi L, Qiao RF, Woo SL, Chen SH, Ronai Z
- Issue date: 2002 Sep
- Amino-terminal-derived JNK fragment alters expression and activity of c-Jun, ATF2, and p53 and increases H2O2-induced cell death.
- Authors: Buschmann T, Yin Z, Bhoumik A, Ronai Z
- Issue date: 2000 Jun 2
- Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment.
- Authors: Bhoumik A, Ivanov V, Ronai Z
- Issue date: 2001 Feb
- TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways.
- Authors: Min W, Pober JS
- Issue date: 1997 Oct 1
- The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.
- Authors: Hayakawa J, Depatie C, Ohmichi M, Mercola D
- Issue date: 2003 Jun 6